These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33290772)

  • 1. Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.
    Scurlock AM; Burks AW; Sicherer SH; Leung DYM; Kim EH; Henning AK; Dawson P; Lindblad RW; Berin MC; Cho CB; Davidson WF; Plaut M; Sampson HA; Wood RA; Jones SM;
    J Allergy Clin Immunol; 2021 Mar; 147(3):992-1003.e5. PubMed ID: 33290772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.
    Jones SM; Sicherer SH; Burks AW; Leung DY; Lindblad RW; Dawson P; Henning AK; Berin MC; Chiang D; Vickery BP; Pesek RD; Cho CB; Davidson WF; Plaut M; Sampson HA; Wood RA;
    J Allergy Clin Immunol; 2017 Apr; 139(4):1242-1252.e9. PubMed ID: 28091362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results.
    Pongracic JA; Gagnon R; Sussman G; Siri D; Oriel RC; Brown-Whitehorn TF; Green TD; Campbell DE; Anvari S; Berger WE; Bird JA; Chan ES; Cheema A; Chinthrajah RS; Chong HJ; Dowling PJ; Fineman SM; Fleischer DM; Gonzalez-Reyes E; Kim EH; Lanser BJ; MacGinnitie A; Mehta H; Petroni D; Rupp N; Schneider LC; Scurlock AM; Sher LD; Shreffler WG; Sindher SB; Stillerman A; Wood R; Yang WH; Bois T; Sampson HA; Bégin P
    J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1864-1873.e10. PubMed ID: 34848381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy.
    Nozawa A; Okamoto Y; Movérare R; Borres MP; Kurihara K
    Pediatr Allergy Immunol; 2014 Jun; 25(4):323-8. PubMed ID: 24953293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
    Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.
    Fleischer DM; Shreffler WG; Campbell DE; Green TD; Anvari S; Assa'ad A; Bégin P; Beyer K; Bird JA; Brown-Whitehorn T; Byrne A; Chan ES; Cheema A; Chinthrajah S; Chong HJ; Davis CM; Ford LS; Gagnon R; Greenhawt M; Hourihane JO; Jones SM; Kim EH; Lange L; Lanser BJ; Leonard S; Mahler V; Maronna A; Nowak-Wegrzyn A; Oriel RC; O'Sullivan M; Petroni D; Pongracic JA; Prescott SL; Schneider LC; Smith P; Staab D; Sussman G; Wood R; Yang WH; Lambert R; Peillon A; Bois T; Sampson HA
    J Allergy Clin Immunol; 2020 Oct; 146(4):863-874. PubMed ID: 32659313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
    Fleischer DM; Greenhawt M; Sussman G; Bégin P; Nowak-Wegrzyn A; Petroni D; Beyer K; Brown-Whitehorn T; Hebert J; Hourihane JO; Campbell DE; Leonard S; Chinthrajah RS; Pongracic JA; Jones SM; Lange L; Chong H; Green TD; Wood R; Cheema A; Prescott SL; Smith P; Yang W; Chan ES; Byrne A; Assa'ad A; Bird JA; Kim EH; Schneider L; Davis CM; Lanser BJ; Lambert R; Shreffler W
    JAMA; 2019 Mar; 321(10):946-955. PubMed ID: 30794314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities.
    Davis CM; Lange L; Beyer K; Fleischer DM; Ford L; Sussman G; Oriel RC; Pongracic JA; Shreffler W; Bee KJ; Campbell DE; Green TD; Lambert R; Peillon A; Bégin P
    J Allergy Clin Immunol Glob; 2023 Feb; 2(1):69-75. PubMed ID: 37780103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
    Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
    J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
    Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
    J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial.
    Sampson HA; Shreffler WG; Yang WH; Sussman GL; Brown-Whitehorn TF; Nadeau KC; Cheema AS; Leonard SA; Pongracic JA; Sauvage-Delebarre C; Assa'ad AH; de Blay F; Bird JA; Tilles SA; Boralevi F; Bourrier T; Hébert J; Green TD; Gerth van Wijk R; Knulst AC; Kanny G; Schneider LC; Kowalski ML; Dupont C
    JAMA; 2017 Nov; 318(18):1798-1809. PubMed ID: 29136445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
    Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.
    Burk CM; Kulis M; Leung N; Kim EH; Burks AW; Vickery BP
    Clin Exp Allergy; 2016 Feb; 46(2):347-53. PubMed ID: 26362760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy.
    Dupont C; Burks AW; Fleischer DM; Bee KJ; Chainani S; Sampson HA
    Expert Rev Clin Immunol; 2024 Jun; 20(6):623-633. PubMed ID: 38323337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy.
    Wisniewski JA; Commins SP; Agrawal R; Hulse KE; Yu MD; Cronin J; Heymann PW; Pomes A; Platts-Mills TA; Workman L; Woodfolk JA
    Clin Exp Allergy; 2015 Jul; 45(7):1201-13. PubMed ID: 25823600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epicutaneous immunotherapy for peanut allergy modifies IgG
    Koppelman SJ; Peillon A; Agbotounou W; Sampson HA; Martin L
    J Allergy Clin Immunol; 2019 Mar; 143(3):1218-1221.e4. PubMed ID: 30389411
    [No Abstract]   [Full Text] [Related]  

  • 18. IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
    Dreskin SC; Germinaro M; Reinhold D; Chen X; Vickery BP; Kulis M; Burks AW; Negi SS; Braun W; Chambliss JM; Eglite S; McNulty CMG
    Pediatr Allergy Immunol; 2019 Dec; 30(8):817-823. PubMed ID: 31437325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
    DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.